Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments, today announced the appointment of Dr. Juergen Heitmann to its Board of Directors
RIEHEN, SWITZERLAND, August 16, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments, today announced the appointment of Dr. Juergen Heitmann to its Board of Directors. The addition of Dr. Heitmann supports the company’s innovative research to target cell-to-cell communication in order to promote an increase in efficiency of the immune response to tumor cells.
Dr. Heitmann, who has more than 25 years of experience in the pharmaceutical industry, specializes in business development strategy, deal negotiation, search & evaluation, due diligence, and commercial assessment.
“Ymmunobio has brought together world-class leaders in CEACAM biology, immunology, and cancer drug development,” said Dr. Heitmann. “As a board member, I’m excited to contribute to Ymmunobio’s significant effort to develop CEACAM antibodies as a novel treatment for cancer.”
Dr. Heitmann is currently director of Business Development at Nordic Pharma. Most recently, he was the CBO at Sensorion, a specialty player in the field of gene therapy. During his career, he has worked at McKinsey & Company, Novartis, Nycomed and Takeda in various roles mostly related to Business Development. He has been active in the biotech and venture capital community for several years as an advisor, part-time manager and board member. A biologist by training, Dr. Heitmann earned his PhD from the University of Tuebingen, Germany.
ABOUT YMMUNOBIO
Ymmunobio AG, a preclinical stage oncology biotech company developing a proprietary class of CEACAM1 antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets the CEACAM receptors that plays a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany.
Contact: Dr. Katrin Rupalla, info@ymmuno.bio